Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCLПодробнее

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphomaПодробнее

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

Dr. Zelenetz on Zanubrutinib Research in MCLПодробнее

Dr. Zelenetz on Zanubrutinib Research in MCL

Novel therapies for patients with MCL after failed response to BTK inhibitorsПодробнее

Novel therapies for patients with MCL after failed response to BTK inhibitors

Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCLПодробнее

$Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL$

Dr. Rule on the FDA Approval of Zanubrutinib in MCLПодробнее

Dr. Rule on the FDA Approval of Zanubrutinib in MCL

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCLПодробнее

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinibПодробнее

Dr. Leslie on Sequencing Zanubrutinib in MCLПодробнее

Dr. Leslie on Sequencing Zanubrutinib in MCL

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitorsПодробнее

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

Bendamustine/Rituximab as Induction Therapy in MCLПодробнее

Bendamustine/Rituximab as Induction Therapy in MCL

Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCLПодробнее

$Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL$

Patient Profile - Susan PruittПодробнее

The value of MRD assessment in lymphomaПодробнее

The value of MRD assessment in lymphoma

BRUIN MCL-321: Pirtobrutinib in BTKi naïve MCLПодробнее

BRUIN MCL-321: Pirtobrutinib in BTKi naïve MCL

Successful use of zanubrutinib for R/R MCL in ChinaПодробнее

Successful use of zanubrutinib for R/R MCL in China

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphomaПодробнее

$Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma$

Differentiating BTK Inhibitor Mechanisms of Action in MCLПодробнее

Differentiating BTK Inhibitor Mechanisms of Action in MCL

Daniel Hinshaw, MD - Video ProfileПодробнее